Regeneron Pharmaceuticals, Inc. (0R2M.L)
USD 587.46
(-4.56%)
USD 587.46
(-4.56%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 2.7 Billion USD | 0.06% |
| 2022 | 2.7 Billion USD | 0.06% |
| 2021 | 2.69 Billion USD | 0.15% |
| 2020 | 2.69 Billion USD | 277.6% |
| 2019 | 713.9 Million USD | 0.76% |
| 2018 | 708.5 Million USD | 0.72% |
| 2017 | 703.45 Million USD | 46.21% |
| 2016 | 481.12 Million USD | 28.13% |
| 2015 | 375.51 Million USD | -18.2% |
| 2014 | 459.06 Million USD | -9.19% |
| 2013 | 505.51 Million USD | 10.54% |
| 2012 | 457.32 Million USD | 5.0% |
| 2011 | 435.53 Million USD | 172.16% |
| 2010 | 160.03 Million USD | 0.0% |
| 2009 | - USD | -100.0% |
| 2008 | 5.09 Million USD | 0.0% |
| 2007 | - USD | -100.0% |
| 2006 | 200 Million USD | 0.0% |
| 2005 | 200 Million USD | 0.0% |
| 2004 | 200 Million USD | 0.0% |
| 2003 | 200 Million USD | 0.0% |
| 2002 | 200 Million USD | -0.07% |
| 2001 | 200.15 Million USD | 9573.76% |
| 2000 | 2.06 Million USD | -23.37% |
| 1999 | 2.7 Million USD | -12.9% |
| 1998 | 3.1 Million USD | -18.42% |
| 1997 | 3.8 Million USD | -25.49% |
| 1996 | 5.1 Million USD | -15.0% |
| 1995 | 6 Million USD | -34.78% |
| 1994 | 9.2 Million USD | 55.93% |
| 1993 | 5.9 Million USD | 1.72% |
| 1992 | 5.8 Million USD | 141.67% |
| 1991 | 2.4 Million USD | 0.0% |
| 1990 | - USD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 1.98 Billion USD | 0.02% |
| 2024 Q3 | 2.7 Billion USD | 0.02% |
| 2024 Q2 | 1.98 Billion USD | 0.02% |
| 2023 Q1 | 2.7 Billion USD | 0.01% |
| 2023 Q2 | 2.7 Billion USD | 0.01% |
| 2023 FY | 2.7 Billion USD | 0.06% |
| 2023 Q3 | 2.7 Billion USD | 0.01% |
| 2023 Q4 | 2.7 Billion USD | 0.01% |
| 2022 Q2 | 1.98 Billion USD | -26.65% |
| 2022 Q4 | 2.7 Billion USD | 0.01% |
| 2022 FY | 2.7 Billion USD | 0.06% |
| 2022 Q1 | 2.7 Billion USD | 0.03% |
| 2022 Q3 | 2.7 Billion USD | 36.37% |
| 2021 Q3 | 1.97 Billion USD | 0.02% |
| 2021 Q4 | 2.69 Billion USD | 36.38% |
| 2021 Q1 | 1.97 Billion USD | -26.59% |
| 2021 FY | 2.69 Billion USD | 0.15% |
| 2021 Q2 | 1.97 Billion USD | 0.02% |
| 2020 FY | 2.69 Billion USD | 277.6% |
| 2020 Q4 | 2.69 Billion USD | 0.03% |
| 2020 Q1 | 715.2 Million USD | 0.18% |
| 2020 Q2 | 715.9 Million USD | 0.1% |
| 2020 Q3 | 2.69 Billion USD | 276.42% |
| 2019 Q3 | 712.7 Million USD | 0.2% |
| 2019 Q4 | 713.9 Million USD | 0.17% |
| 2019 Q2 | 711.3 Million USD | 0.2% |
| 2019 Q1 | 709.9 Million USD | 0.2% |
| 2019 FY | 713.9 Million USD | 0.76% |
| 2018 Q3 | 707.2 Million USD | 0.18% |
| 2018 Q1 | 704.64 Million USD | 0.17% |
| 2018 FY | 708.5 Million USD | 0.72% |
| 2018 Q2 | 705.9 Million USD | 0.18% |
| 2018 Q4 | 708.5 Million USD | 0.18% |
| 2017 FY | 703.45 Million USD | 46.21% |
| 2017 Q3 | 702.31 Million USD | 0.16% |
| 2017 Q4 | 703.45 Million USD | 0.16% |
| 2017 Q1 | 700.4 Million USD | 45.58% |
| 2017 Q2 | 701.17 Million USD | 0.11% |
| 2016 Q4 | 481.12 Million USD | 25.87% |
| 2016 FY | 481.12 Million USD | 28.13% |
| 2016 Q2 | 361.52 Million USD | -0.2% |
| 2016 Q3 | 382.22 Million USD | 5.73% |
| 2016 Q1 | 362.23 Million USD | -3.54% |
| 2015 Q2 | 388.04 Million USD | -17.87% |
| 2015 Q1 | 472.47 Million USD | 2.92% |
| 2015 Q4 | 375.51 Million USD | -4.9% |
| 2015 Q3 | 394.86 Million USD | 1.76% |
| 2015 FY | 375.51 Million USD | -18.2% |
| 2014 Q4 | 459.06 Million USD | -18.61% |
| 2014 FY | 459.06 Million USD | -9.19% |
| 2014 Q1 | 530.05 Million USD | 4.85% |
| 2014 Q2 | 516.78 Million USD | -2.5% |
| 2014 Q3 | 564.06 Million USD | 9.15% |
| 2013 Q3 | 481.38 Million USD | 1.88% |
| 2013 Q2 | 472.5 Million USD | 2.44% |
| 2013 Q1 | 461.27 Million USD | 0.86% |
| 2013 FY | 505.51 Million USD | 10.54% |
| 2013 Q4 | 505.51 Million USD | 5.01% |
| 2012 Q4 | 457.32 Million USD | 1.53% |
| 2012 Q2 | 445.04 Million USD | 1.21% |
| 2012 Q1 | 439.74 Million USD | 1.2% |
| 2012 FY | 457.32 Million USD | 5.0% |
| 2012 Q3 | 450.45 Million USD | 1.22% |
| 2011 Q1 | 160.15 Million USD | 0.08% |
| 2011 Q4 | 434.52 Million USD | 172.46% |
| 2011 FY | 435.53 Million USD | 172.16% |
| 2011 Q2 | 159.45 Million USD | -0.43% |
| 2011 Q3 | 159.48 Million USD | 0.02% |
| 2010 Q1 | 156.46 Million USD | 0.0% |
| 2010 Q2 | 157.35 Million USD | 0.57% |
| 2010 Q3 | 158.38 Million USD | 0.65% |
| 2010 Q4 | 160.03 Million USD | 1.04% |
| 2010 FY | 160.03 Million USD | 0.0% |
| 2009 Q4 | - USD | -100.0% |
| 2009 Q1 | - USD | -100.0% |
| 2009 Q3 | 62.57 Million USD | -0.56% |
| 2009 FY | - USD | -100.0% |
| 2009 Q2 | 62.92 Million USD | 0.0% |
| 2008 FY | 5.09 Million USD | 0.0% |
| 2008 Q2 | - USD | 0.0% |
| 2008 Q3 | - USD | 0.0% |
| 2008 Q4 | 5.09 Million USD | 0.0% |
| 2008 Q1 | - USD | 0.0% |
| 2007 Q2 | 200 Million USD | 0.0% |
| 2007 Q3 | 200 Million USD | 0.0% |
| 2007 Q4 | - USD | -100.0% |
| 2007 FY | - USD | -100.0% |
| 2007 Q1 | 200 Million USD | 0.0% |
| 2006 Q3 | 200 Million USD | 0.0% |
| 2006 Q1 | 200 Million USD | 0.0% |
| 2006 FY | 200 Million USD | 0.0% |
| 2006 Q2 | 200 Million USD | 0.0% |
| 2006 Q4 | 200 Million USD | 0.0% |
| 2005 Q4 | 200 Million USD | 0.0% |
| 2005 Q3 | 200 Million USD | 0.0% |
| 2005 Q2 | 200 Million USD | 0.0% |
| 2005 Q1 | 200 Million USD | 0.0% |
| 2005 FY | 200 Million USD | 0.0% |
| 2004 Q3 | 200 Million USD | 0.0% |
| 2004 Q2 | 200 Million USD | 0.0% |
| 2004 FY | 200 Million USD | 0.0% |
| 2004 Q4 | 200 Million USD | 0.0% |
| 2004 Q1 | 200 Million USD | 0.0% |
| 2003 Q2 | 205.14 Million USD | 2.57% |
| 2003 FY | 200 Million USD | 0.0% |
| 2003 Q4 | 200 Million USD | 0.0% |
| 2003 Q3 | 200 Million USD | -2.51% |
| 2003 Q1 | 200 Million USD | 0.0% |
| 2002 Q3 | 200 Million USD | 0.0% |
| 2002 Q4 | 200 Million USD | 0.0% |
| 2002 Q1 | 200.05 Million USD | -0.05% |
| 2002 Q2 | 200 Million USD | -0.03% |
| 2002 FY | 200 Million USD | -0.07% |
| 2001 Q4 | 200.15 Million USD | 12059.78% |
| 2001 FY | 200.15 Million USD | 9573.76% |
| 2001 Q1 | 1.91 Million USD | -7.49% |
| 2001 Q2 | 1.74 Million USD | -8.62% |
| 2001 Q3 | 1.64 Million USD | -5.89% |
| 2000 FY | 2.06 Million USD | -23.37% |
| 2000 Q1 | 2.52 Million USD | -6.67% |
| 2000 Q3 | 2.17 Million USD | -6.81% |
| 2000 Q2 | 2.33 Million USD | -7.3% |
| 2000 Q4 | 2.06 Million USD | -4.96% |
| 1999 Q1 | 2.8 Million USD | -9.68% |
| 1999 FY | 2.7 Million USD | -12.9% |
| 1999 Q3 | 2.1 Million USD | -16.0% |
| 1999 Q2 | 2.5 Million USD | -10.71% |
| 1999 Q4 | 2.7 Million USD | 28.57% |
| 1998 Q1 | 3.5 Million USD | -7.89% |
| 1998 Q2 | 3.6 Million USD | 2.86% |
| 1998 Q3 | 2.7 Million USD | -25.0% |
| 1998 Q4 | 3.1 Million USD | 14.81% |
| 1998 FY | 3.1 Million USD | -18.42% |
| 1997 Q1 | 4.4 Million USD | -13.73% |
| 1997 FY | 3.8 Million USD | -25.49% |
| 1997 Q3 | 4.1 Million USD | -2.38% |
| 1997 Q4 | 3.8 Million USD | -7.32% |
| 1997 Q2 | 4.2 Million USD | -4.55% |
| 1996 Q1 | 4.9 Million USD | -18.33% |
| 1996 Q4 | 5.1 Million USD | -1.92% |
| 1996 Q3 | 5.2 Million USD | 6.12% |
| 1996 FY | 5.1 Million USD | -15.0% |
| 1996 Q2 | 4.9 Million USD | 0.0% |
| 1995 Q1 | 8.6 Million USD | -6.52% |
| 1995 Q3 | 7 Million USD | -9.09% |
| 1995 Q4 | 6 Million USD | -14.29% |
| 1995 Q2 | 7.7 Million USD | -10.47% |
| 1995 FY | 6 Million USD | -34.78% |
| 1994 Q2 | 7.2 Million USD | -11.11% |
| 1994 Q1 | 8.1 Million USD | 37.29% |
| 1994 FY | 9.2 Million USD | 55.93% |
| 1994 Q4 | 9.2 Million USD | 15.0% |
| 1994 Q3 | 8 Million USD | 11.11% |
| 1993 Q3 | 6.2 Million USD | -1.59% |
| 1993 FY | 5.9 Million USD | 1.72% |
| 1993 Q2 | 6.3 Million USD | 0.0% |
| 1993 Q1 | 6.3 Million USD | 8.62% |
| 1993 Q4 | 5.9 Million USD | -4.84% |
| 1992 Q4 | 5.8 Million USD | 11.54% |
| 1992 Q3 | 5.2 Million USD | 8.33% |
| 1992 Q2 | 4.8 Million USD | 17.07% |
| 1992 Q1 | 4.1 Million USD | 70.83% |
| 1992 FY | 5.8 Million USD | 141.67% |
| 1991 Q3 | 700 Thousand USD | 133.33% |
| 1991 FY | 2.4 Million USD | 0.0% |
| 1991 Q2 | 300 Thousand USD | 0.0% |
| 1991 Q4 | 2.4 Million USD | 242.86% |
| 1990 Q4 | - USD | 0.0% |
| 1990 FY | - USD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| uniQure N.V. | 130.06 Million USD | -1978.115% |
| Agios Pharmaceuticals, Inc. | 56.98 Million USD | -4642.928% |
| Amicus Therapeutics, Inc. | 387.85 Million USD | -596.879% |
| Atara Biotherapeutics, Inc. | 45.69 Million USD | -5815.348% |
| bluebird bio, Inc. | 224.41 Million USD | -1104.399% |
| Cara Therapeutics, Inc. | 37.07 Million USD | -7189.571% |
| Imunon, Inc. | 1.13 Million USD | -237143.624% |
| Editas Medicine, Inc. | 24.37 Million USD | -10990.185% |
| IQVIA Holdings Inc. | 12.95 Billion USD | 79.136% |
| Mettler-Toledo International Inc. | 1.97 Billion USD | -36.818% |
| Myriad Genetics, Inc. | 130.9 Million USD | -1964.859% |
| Neurocrine Biosciences, Inc. | 258.3 Million USD | -946.419% |
| Supernus Pharmaceuticals, Inc. | 33.19 Million USD | -8042.246% |
| Verastem, Inc. | 40.08 Million USD | -6642.753% |
| Walgreens Boots Alliance, Inc. | 8.04 Billion USD | 66.399% |
| Waters Corporation | 2.3 Billion USD | -17.236% |
| Thermo Fisher Scientific Inc. | 31.3 Billion USD | 91.367% |
| Biogen Inc. | 7.18 Billion USD | 62.398% |
| Nektar Therapeutics | 112.62 Million USD | -2299.911% |
| Perrigo Company plc | 3.63 Billion USD | 25.597% |
| Dynavax Technologies Corporation | 252.41 Million USD | -970.803% |
| Illumina, Inc. | 1.48 Billion USD | -81.525% |
| Corbus Pharmaceuticals Holdings, Inc. | 3.23 Million USD | -83358.103% |
| Iovance Biotherapeutics, Inc. | 1 Million USD | -270190.0% |
| Heron Therapeutics, Inc. | 173.75 Million USD | -1455.599% |
| Unity Biotechnology, Inc. | 23.53 Million USD | -11382.646% |
| BioMarin Pharmaceutical Inc. | 593.09 Million USD | -355.728% |
| Sangamo Therapeutics, Inc. | 33.51 Million USD | -7964.747% |
| Evolus, Inc. | 120.35 Million USD | -2145.698% |
| Adicet Bio, Inc. | 17.7 Million USD | -15168.034% |
| Aclaris Therapeutics, Inc. | 3.07 Million USD | -87827.781% |
| Esperion Therapeutics, Inc. | 501.54 Million USD | -438.914% |
| FibroGen, Inc. | 89.69 Million USD | -2913.367% |
| Agilent Technologies, Inc. | 2.73 Billion USD | 1.174% |
| OPKO Health, Inc. | 222.03 Million USD | -1117.336% |
| Homology Medicines, Inc. | 43.17 Million USD | -6160.191% |
| Geron Corporation | 35.05 Million USD | -7611.335% |
| Alnylam Pharmaceuticals, Inc. | 2.34 Billion USD | -15.359% |
| Exelixis, Inc. | 189.94 Million USD | -1322.998% |
| Viking Therapeutics, Inc. | 936 Thousand USD | -288671.368% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| Intellia Therapeutics, Inc. | 96.74 Million USD | -2693.782% |
| Zoetis Inc. | 6.56 Billion USD | 58.822% |
| Axsome Therapeutics, Inc. | 178.07 Million USD | -1417.886% |
| Abeona Therapeutics Inc. | 4.4 Million USD | -61301.636% |
| Vertex Pharmaceuticals Incorporated | 724.7 Million USD | -272.968% |
| Kala Pharmaceuticals, Inc. | 34.19 Million USD | -7805.528% |
| Ionis Pharmaceuticals, Inc. | 1.4 Billion USD | -93.012% |
| Sarepta Therapeutics, Inc. | 1.13 Billion USD | -138.664% |
| Corcept Therapeutics Incorporated | - USD | -Infinity% |
| Halozyme Therapeutics, Inc. | 1.49 Billion USD | -80.284% |
| Blueprint Medicines Corporation | 610.96 Million USD | -342.401% |
| Insmed Incorporated | 1.19 Billion USD | -126.496% |
| TG Therapeutics, Inc. | 100.11 Million USD | -2599.714% |
| Incyte Corporation | 29.16 Million USD | -9168.569% |
| Emergent BioSolutions Inc. | 446.5 Million USD | -505.353% |